CD274 and neoplasm: From these CAR T trials we have learned that engineered CAR T cells can cross the BBB and home to the tumor site in the brain, and that PDL1 is upregulated after CAR T treatment, suggesting a possible role in the loss of CAR T cell function in GBM and that providing CPI Ab is not sufficient to improve the therapy.